Protocol Ledger

NCT04614103 · Phase II · RECRUITING

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Interventional Phase II clinical trial protocol NCT04614103 sponsored by Iovance Biotherapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-07 Enrollment: 170 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04614103
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)170 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04614103
Protocol FieldVerified Registry Value
NCT IdentifierNCT04614103
Consolidated Lead SponsorIovance Biotherapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment170 participants (ESTIMATED)
Registered Start Date2021-05-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04614103
Hospital Research SiteLocationSite Profile
Moffitt Cancer CenterTampa, FLOpen Hospital Dossier ->
Rush University Medical CenterChicago, ILOpen Hospital Dossier ->
University of LouisvilleLouisville, KYOpen Hospital Dossier ->
University of MarylandBaltimore, MDOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI